Resource Library
Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.
Related Resources
July 12, 2021
Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL
13th Annual T-Cell Lymphoma Forum
Other
Read More
June 20, 2021
KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models
16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting
Other
Read More
April 10, 2021
Mechanisms Underlying Synergistic Activity of KT-413, a Targeted Degrader of IRAK4 and IMiD Substrates in Hematopoietic Cancers
American Association of Cancer Research (AACR) 2021 Annual Meeting
Other
Read More
February 16, 2021
Targeted Protein Degradation in Oncology and Beyond
2nd Annual North American Protein Degradation Congress
February 16, 2021
Discovery of Potent and Selective STAT3 Targeted Protein Degraders with Excellent in vitro and in vivo ADME Properties
Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC
Other
Read More
December 7, 2020
KTX-120, A Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL Cell and Patient Derived Xenograft Models
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Other
Read More
December 7, 2020
Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Other
Read More
December 7, 2020
Mechanisms of Anti-Tumor Activity of STAT3 Degraders in Lymphoma
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Other
Read More
October 15, 2020
Targeted Protein Degradation Beyond Oncology
3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi
June 22, 2020
IRAKIMiDs: Protein degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broad activity with durable regressions in MYD88 mutant lymphoma xenografts in vivo
American Association for Cancer Research (AACR) Virtual Annual Meeting II
Other
Read More